Technical Briefing: Accuray, Antares Pharma, Chelsea Therapeutics, and Anthera Pharma

LONDON, July 26, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

 

The U.S. equity market managed to post gains on Thursday, July 25, 2013. Both Dow Jones and the S&P 500 remained in red for most part of the day. However, a recovery in late trading hours helped the indices to end higher. Shares in the healthcare sector ended on a mixed note even as the broader market edged higher. The major movers in the sector included Accuray Incorporated (NASDAQ: ARAY), Antares Pharma Inc. (NASDAQ: ATRS), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). All these companies are tracked by AAAResearchReports.com. Free technical research reports on ARAY, ATRS, CHTP, and ANTH can be accessed by signing up at:

http://www.aaaresearchreports.com/register/  

Shares in Accuray Inc. moved higher on Thursday, tracking gains in the broader market. The company's shares ended the day 1.48% higher at $6.18 after fluctuating between $6.01 and $6.24. A total of 1.65 million shares were traded which is more than the daily average volume of 883,060. Accuray's shares have gained 1.64% in the last three trading sessions and 13.60% in the last one month, thus outperforming the S&P 500. Moreover, the stock is currently trading above its 50-day and 200-day moving averages. Download free report on ARAY upon registration at:

http://www.AAAResearchReports.com/ARAY072613.pdf

Antares Pharma Inc.'s stock rallied on Thursday, reversing all of its losses from previous trading sessions. The company's shares ended the day 4.96% higher at $4.44 after oscillating between $4.19 and $4.48. A total of 857,902 shares were traded which is below the daily average volume of 946,051. Antares Pharma's shares have advanced by 0.91% in the last three trading sessions, thus outperforming the S&P 500. Furthermore, the stock is currently trading above its 50-day and 200-day moving averages. ATRS technical report can be accessed for free by signing up at:

http://www.AAAResearchReports.com/ATRS072613.pdf

Shares in Chelsea Therapeutics International Ltd fell sharply on Thursday, extending their losses from previous trading sessions. The company's shares fluctuated between $3.01 and $3.15 before finishing the day 1.59% lower at $3.09. A total of 1.20 million shares were traded which is below the daily average volume of 1.35 million. Chelsea Therapeutics International's shares have fallen by 3.13% in the last three trading sessions. Despite the recent pullback, the stock is currently trading near its 52-week high of $3.25. A free report on CHTP can be accessed by registering at:

http://www.AAAResearchReports.com/CHTP072613.pdf

Anthera Pharmaceuticals Inc.'s stock slipped on Thursday even as the broader market edged higher. The company's shares oscillated between $4.19 and $4.30 before finishing the day 1.62% lower at $4.26. A total of 66,862 shares were traded which is below the daily average volume of 120,522. The company's shares have dropped by 2.74% in the last three trading sessions, and 8.74% in the last three months, underperforming the S&P 500. Register with AAA Research Reports and download research on ANTH for free at:

http://www.AAAResearchReports.com/ANTH072613.pdf

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE AAA Research Reports




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.